Join a panel of BKD Trusted Advisors and HFMA for a discussion on the reimbursement implications of the IPPS and OPPS final rule for federal fiscal year 2021, changes to the 340B drug program, recent actions by participating drug manufacturers, and more regulatory updates as looming requirements come to fruition in the coming weeks. 

Learning Objectives

Upon completion of this program, participants will be able to:

  • Discuss the highlights and reimbursement implications of the Medicare Final Rule for the FYE 9/30/21 
  • Describe changes to 340B drug payments and trends in this program 
  • Identify updates to other looming and impending regulatory issues 

The information contained in these slides is based on the information available as of the date of this live presentation and is subject to change. The content was presented for illustrative purposes and your information only. Applying this information to your situation requires careful consideration of facts, circumstances, and timing of requirements. Consult your BKD advisor or legal counsel to apply to your unique situation and circumstances.

Related FORsights

Let's Connect

Subscribe to our content or get in touch with us today

Subscribe Contact Us